Showing results (11-20 of 100) with videos related to
Sort By:
Pageof 10
European Journal of Pharmacology|May 7, 1998
A role of nitric oxide in WIN 55,212-2 tolerance in miceE Spina, A Trovati, D Parolaro, et al.Therapeutic Drug Monitoring|December 16, 1998
Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophreniaG Facciolà, A Avenoso, E Spina, et al.Journal of Chromatography. B, Biomedical Sciences and Applications|November 15, 2000
Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detectionA Avenoso, G Facciolà, M Salemi, et al.Carbohydrate Research|July 11, 1998
The structure of the exocellular polysaccharide from the cyanobacterium Cyanospira capsulataD Garozzo, G Impallomeni, E Spina, et al.Clinical Pharmacology and Therapeutics|March 1, 1987
Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotypeE Spina, E Steiner, O Ericsson, et al.Journal of Mass Spectrometry : JMS|September 6, 2000
Sequencing of oligosaccharides by collision-induced dissociation matrix-assisted laser desorption/ionization mass spectrometryE Spina, R Cozzolino, E Ryan, et al.Clinical Pharmacology and Therapeutics|May 1, 1988
Inhibition of desipramine 2-hydroxylation by quinidine and quinineE Steiner, E Dumont, E Spina, et al.Functional Neurology|October 1, 1987
Prevalence of cardiac conduction disturbances during carbamazepine treatment: preliminary dataE Spina, G Kenneback, L Bergfeldt, et al.Therapeutic Drug Monitoring|November 1, 1989
Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping testsE Spina, A L Buemi, E Sanz, et al.Therapeutic Drug Monitoring|October 16, 1999
No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteersA Avenoso, G Facciolà, M G Scordo, et al.Pageof 10